|
|
|
|
LEADER |
02686nam a22004215i 4500 |
001 |
000289904 |
005 |
20210601090858.0 |
007 |
cr nn 008mamaa |
008 |
131004s2013 gw | s |||| 0|eng d |
020 |
|
|
|a 9783642386640
|
024 |
7 |
|
|a 10.1007/978-3-642-38664-0
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Pharmacotherapy of Pulmonary Hypertension /
|c edited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch.
|
250 |
|
|
|a 1st ed. 2013.
|
260 |
# |
# |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2013.
|
300 |
|
|
|a IX, 576 p. 66 illus., 56 illus. in color. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Handbook of Experimental Pharmacology,
|v 218
|
505 |
0 |
|
|a Preface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
0 |
|a Internal medicine.
|
650 |
|
0 |
|a Respiratory organs—Diseases.
|
650 |
|
0 |
|a Laboratory medicine.
|
650 |
|
0 |
|a Molecular biology.
|
650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
650 |
2 |
4 |
|a Internal Medicine.
|
650 |
2 |
4 |
|a Pneumology/Respiratory System.
|
650 |
2 |
4 |
|a Laboratory Medicine.
|
650 |
2 |
4 |
|a Molecular Medicine.
|
700 |
1 |
|
|a Humbert, Marc.
|e editor.
|
700 |
1 |
|
|a Evgenov, Oleg V.
|e editor.
|
700 |
1 |
|
|a Stasch, Johannes-Peter.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|